Galectin Therapeutics (GALT) Interest Expenses (2018 - 2026)

Galectin Therapeutics has reported Interest Expenses for 9 years, with the latest figure at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 13.99% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 21.52% YoY), and the FY2025 full-year result was $7.3 million, up 32.29% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.0 million, up from $1.9 million in the prior quarter.
• The five-year high for Interest Expenses was $2.0 million in Q1 2026, with the low at $227000.0 in Q1 2022.
• Average Interest Expenses over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Interest Expenses soared 3742.86% in 2022 and advanced 12.41% in 2025.
• Tracing GALT's Interest Expenses over 5 years: stood at $308000.0 in 2022, then surged by 175.0% to $847000.0 in 2023, then soared by 103.66% to $1.7 million in 2024, then rose by 12.41% to $1.9 million in 2025, then gained by 2.53% to $2.0 million in 2026.
• The last three Interest Expenses figures came in at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.

Peer Comparison